Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

A phase I study of myo-inositol for lung cancer chemoprevention.

Lam S, McWilliams A, LeRiche J, MacAulay C, Wattenberg L, Szabo E.

Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1526-31.

2.

A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia.

Lam S, MacAulay C, Le Riche JC, Dyachkova Y, Coldman A, Guillaud M, Hawk E, Christen MO, Gazdar AF.

J Natl Cancer Inst. 2002 Jul 3;94(13):1001-9.

3.

Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.

Lam S, Xu X, Parker-Klein H, Le Riche JC, Macaulay C, Guillaud M, Coldman A, Gazdar A, Lotan R.

Int J Oncol. 2003 Dec;23(6):1607-13.

PMID:
14612933
4.

Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS.

Gerli S, Papaleo E, Ferrari A, Di Renzo GC.

Eur Rev Med Pharmacol Sci. 2007 Sep-Oct;11(5):347-54.

PMID:
18074942
6.
7.

Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.

Costantino D, Minozzi G, Minozzi E, Guaraldi C.

Eur Rev Med Pharmacol Sci. 2009 Mar-Apr;13(2):105-10.

PMID:
19499845
8.

Suppression of lung and liver carcinogenesis in mice by oral administration of myo-inositol.

Nishino H, Murakoshi M, Masuda M, Tokuda H, Satomi Y, Onozuka M, Yamaguchi S, Bu P, Tsuruta A, Nosaka K, Baba M, Takasuka N.

Anticancer Res. 1999 Sep-Oct;19(5A):3663-4.

PMID:
10625935
9.
11.

Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL, particularly in hyperlipidemic subjects with metabolic syndrome.

Maeba R, Hara H, Ishikawa H, Hayashi S, Yoshimura N, Kusano J, Takeoka Y, Yasuda D, Okazaki T, Kinoshita M, Teramoto T.

J Nutr Sci Vitaminol (Tokyo). 2008 Jun;54(3):196-202.

12.
13.

Chemoprevention of pulmonary carcinogenesis by myo-inositol.

Wattenberg LW.

Anticancer Res. 1999 Sep-Oct;19(5A):3659-61.

PMID:
10625934
14.

Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects.

Chandra KP, Shiwalkar A, Kotecha J, Thakkar P, Srivastava A, Chauthaiwale V, Sharma SK, Cross MR, Dutt C.

Clin Drug Investig. 2009;29(9):559-75. doi: 10.2165/11315260-000000000-00000.

PMID:
19663519
16.

Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.

Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T.

J Clin Psychopharmacol. 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce.

PMID:
19440077
17.

[The safety of long-term administration of losartan in current clinical practice: a non-intervention NCT-CZ 14/04/LOZ study].

Krupicka J, Ceypov√° K, Kristenov√° P, Hauser T.

Vnitr Lek. 2008 Nov;54(11):1031-8. Czech.

PMID:
19069675
18.

Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.

Kim SH, Kim YD, Lim DS, Yoon MH, Ahn YK, On YK, Lee JW, Kim IJ, Park JB, Kim JJ, Chung WS, Yang JY, Seo HS, Shin EK, Kim HS; Korean Multicenter Amlodipine Study Investigators.

Clin Ther. 2007 Sep;29(9):1924-36.

PMID:
18035192
19.

Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.

Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A.

Gynecol Endocrinol. 2007 Dec;23(12):700-3. Epub 2007 Oct 10.

PMID:
17952759
20.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk